Description: Novacyt S.A., together with its subsidiaries, engages in developing, manufacturing, and commercializing clinical diagnostic products for cancer and infectious diseases in Africa, Europe, the Asia Pacific, the United States, and the Middle East. The company operates through Corporate and Diagnostics and Molecular Testing segments. The Corporate and Diagnostics segment manufactures and distributes reagents and kits for bacterial and blood tests. The Molecular Testing segment designs, manufactures and distributes test kits for certain diseases in humans, animals, and food products. The company's diagnostic products are used in oncology, microbiology, haematology, and serology testing. It also develops, manufactures, and distributes diagnostic products for food laboratories; and manufactures and supplies reagents, as well as tests for in vitro diagnostic tests and blood grouping application, under the Plasmatec and Biotec brand names. It serves universities, hospitals, clinics, and testing laboratories. The company was founded in 2006 and is based in Camberley, the United Kingdom.
Home Page: www.novacyt.com
131 Boulevard Carnot
Le Vésinet,
78110
France
Phone:
44 2380 748830
Officers
| Name | Title |
|---|---|
| Mr. Lyn Dafydd Rees | CEO & Executive Director |
| Mr. Steve Gibson | CFO & Director |
| Bryan Close | Chief Operations Officer |
| Dr. Joanne Mason | Chief Scientific Officer & Director |
| Mr. David Franks | Chief Human Resources Officer |
| Paul Oladimeji | Group Head of R&D |
Exchange: PINK
Country: US : United States of America
Currency: US Dollar ($)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Health Care Equipment & Services |
| GIC Industry: | Health Care Equipment & Supplies |
| GIC Sub-Industry: | Health Care Equipment |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 0.5571 |
| Price-to-Sales TTM: | 2.6786 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 240 |